AR and cancer: For instance, genomic profiling can reveal mutations in DNA repair genes like BRCA1/2 or alterations in the AR signalling pathway, which can guide the use of targeted therapies such as PARP inhibitors for BRCA-mutated cancers or next-generation AR signalling inhibitors.